Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pinaverium bromide plus Bacillus subtilis/Enterococcus faecium probiotics for functional diarrhea
ChiCTR2600118754Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Feb 2026
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of pinaverium and Medilac-S in functional diarrhea (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Overall symptom relief rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
pinaveriumMedilac-S
03
Conditions
functional diarrhea
Beyond the preview
Go deeper on ChiCTR2600118754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118754.